Copper glycinate
CAS 13479-54-4
Copper glycinate (CAS 13479-54-4) is a pharmaceutical compound with 0 bioactivity targets and 1 adverse event association.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Cross-Reference to Chemicals
Same-CAS substance identity is available in the industrial chemicals vertical.
Copper glycinate is linked to DTXSID40893690 in DSSTox identifiers.
View industrial chemical data →Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Copper glycinate used for in pharmaceutical contexts?
Copper glycinate (CAS 13479-54-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Copper glycinate?
Copper glycinate has 1 DrugCentral/FAERS adverse event association. Rendered reaction terms include Breast cancer. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Copper glycinate also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Copper Glycinate with EU status "restricted".
What clinical phase is Copper glycinate in?
No phase 1-4 clinical development badge is rendered for Copper glycinate because the matched compound identifier rows do not contain a max-phase value.